Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Sells $52,805.79 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Ming Hsieh sold 2,313 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total transaction of $52,805.79. Following the transaction, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Fulgent Genetics Stock Performance

Shares of Fulgent Genetics stock traded up $0.27 during trading on Thursday, hitting $23.12. 97,626 shares of the company’s stock were exchanged, compared to its average volume of 186,510. The business has a 50-day simple moving average of $22.28 and a 200-day simple moving average of $21.99. Fulgent Genetics, Inc. has a 52-week low of $18.91 and a 52-week high of $33.97. The stock has a market capitalization of $691.84 million, a price-to-earnings ratio of -4.15 and a beta of 1.37.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 57.72% and a negative return on equity of 2.92%. The firm had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. During the same quarter last year, the company posted ($0.33) earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. On average, equities analysts anticipate that Fulgent Genetics, Inc. will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its position in shares of Fulgent Genetics by 0.9% in the second quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock valued at $1,338,000 after purchasing an additional 637 shares during the period. Illinois Municipal Retirement Fund grew its position in shares of Fulgent Genetics by 5.6% in the fourth quarter. Illinois Municipal Retirement Fund now owns 12,534 shares of the company’s stock valued at $362,000 after purchasing an additional 668 shares during the period. Signaturefd LLC grew its position in shares of Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Fulgent Genetics by 34.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,569 shares of the company’s stock valued at $190,000 after purchasing an additional 1,667 shares during the period. Finally, Asset Dedication LLC acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $33,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.